FIND is a global non-profit organization that drives innovation in the development and delivery of diagnostics to combat major diseases affecting the world’s poorest populations.

Diagnostics often do not exist, are inaccessible, or cost too much. Despite being pivotal for guiding the best treatment for individual patients; for preventing the spread of disease and antimicrobial resistance; and for enhancing surveillance for early disease detection and monitoring – diagnostics remain under-resourced and overlooked.

With priorities aligned to those of the global public health community, we turn complex diagnostic challenges into simple solutions through unique partnerships with the public, private and non-profit sectors.

FIND is a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation. We have 120 staff based in our Geneva headquarters and 4 regional hubs, working with our partners on over 70 projects that span 6 disease areas.

Our work bridges R&D to access: we have deep technical and practical experience in the definition of needs, development of fit-for-purpose products, generation of evidence for regulators and policy-makers, analysis of market dynamics, the introduction of new products, and strengthening of laboratory systems.

Since 2003, we have been instrumental in the development of 24 new diagnostic tools. Over 50 million FIND-supported products have been provided to 150 low- and middle-income countries since the start of 2015. Our work has been transformative in the diagnosis of tuberculosis and malaria, and helped bring sleeping sickness elimination within reach.

In the next few years we are seeking to achieve multiple diagnostic breakthroughs, from point-of-care tests that will help patients access appropriate treatment for diseases including tuberculosis and hepatitis C, to advances in digital tools to make diagnostic data useful in low-resource settings for clinical care and surveillance.

SUCCESS STORIES

We have been involved in the development and/or delivery of every one of the 10 TB diagnostics recommended by WHO.

We co-developed assays for GeneXpert, a point-of-care (POC) molecular platform that has changed the landscape in TB diagnosis and drug-susceptibility testing: time taken to obtain a test result has been reduced from months to less than 2 hours. GeneXpert is becoming the mainstay of infectious disease diagnosis in low-resource settings, used in more than 130 countries for diseases including HIV (early infant diagnosis), HPV, HCV, and Ebola – as well as TB.

We co-developed the first rapid diagnostic test (RDT) for sleeping sickness and supported its implementation in integrated screening strategies, which has been central to sleeping sickness elimination efforts: 16 African countries are on track to meet WHO targets.

We introduced a systematic, WHO-endorsed assessment of malaria RDTs to help countries buy quality tests, which has transformed the malaria market and enabled test-and-treat strategies for control: 96% of tests now meet quality standards – versus 23% in 2006.

We have been involved in the development and delivery of every one of the 10 TB diagnostics recommended by WHO.

We co-developed assays for GeneXpert, a point-of-care (POC) molecular platform that has changed the landscape in TB diagnosis and drug-susceptibility testing: time taken to obtain a test result has been reduced from months to less than 2 hours. GeneXpert is becoming the mainstay of infectious disease diagnosis in low-resource settings, used in more than 130 countries for diseases including HIV (early infant diagnosis), HPV, HCV, and Ebola – as well as TB.

We co-developed the first rapid diagnostic test (RDT) for sleeping sickness and supported its implementation in integrated screening strategies, which has been central to sleeping sickness elimination efforts: 16 African countries are on track to meet WHO targets.

We introduced a systematic, WHO-endorsed assessment of malaria RDTs to help countries buy quality tests, which has transformed the malaria market and enabled test-and-treat strategies for control: 96% of tests now meet quality standards – versus 23% in 2006.

We have been involved in the development and delivery of every one of the 10 TB diagnostics recommended by WHO.

We co-developed assays for GeneXpert, a point-of-care (POC) molecular platform that has changed the landscape in TB diagnosis and drug-susceptibility testing: time taken to obtain a test result has been reduced from months to less than 2 hours. GeneXpert is becoming the mainstay of infectious disease diagnosis in low-resource settings, used in more than 130 countries for diseases including HIV (early infant diagnosis), HPV, HCV, and Ebola – as well as TB.

We co-developed the first rapid diagnostic test (RDT) for sleeping sickness and supported its implementation in integrated screening strategies, which has been central to sleeping sickness elimination efforts: 16 African countries are on track to meet WHO targets.

We introduced a systematic, WHO-endorsed assessment of malaria RDTs to help countries buy quality tests, which has transformed the malaria market and enabled test-and-treat strategies for control: 96% of tests now meet quality standards – versus 23% in 2006.